Company / Depreciation & Amortization
Cullinan Therapeutics, Inc. Depreciation & Amortization History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$306.0K
FY2024
5-year range
$62.0K / $310.0K
FY2020-FY2024
Trend
-1.3%
vs FY2023
Sector context
#143 of 165
Health Care
What the data says
Cullinan Therapeutics, Inc.'s depreciation & amortization of $306,000 is lower than 87% of companies in the Health Care sector (FY2024). Increased from $93,000 to $306,000 over the past 2 years.
Based on SEC 10-K filings.
$306,000 in FY2024 with a 3-year CAGR of +70.3%.
Increased from $93,000 to $306,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +70.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 165This company $306.0K Sector average $216.8M
▼
-99.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +70.3%, indicating consistent growth.
- In FY2024, depreciation & amortization decreased 1.3% year-over-year.
- Ranks #143 out of 165 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $306.0K | -1.3% |
| FY2023 | $310.0K | +233.3% |
| FY2022 | $93.0K | +50.0% |
| FY2021 | $62.0K | +0.0% |
| FY2020 | $62.0K | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026